This chart shows commonly used chemotherapy regimens in patients with mCRC. Importantly, in patients with mCRC, these chemotherapy regimens are rarely used alone. They are generally combined with a targeted therapy or immunotherapy based on the results of molecular testing.

Chemotherapy Regimens

FOLFOX Oxaliplatin + Leucovorin + 5-FU

Oxaliplatin 85 mg/m² IV Day 1

Leucovorin 400 mg/m² IV Day 1

5-FU 400 mg/m² IV bolus on Day 1, then 1200 mg/m²/day x 2 days via IV continuous infusion

Repeat every 2 weeks

CAPEOX Oxaliplatin + Capecitabine

Oxaliplatin 130 mg/m² IV Day 1

Capecitabine 1000 mg/m² twice daily orally for 14 days^*

Repeat every 3 weeks

FOLFIRI Irinotecan + Leucovorin + 5-FU

Irinotecan 180 mg/m² IV over 30-90 minutes, Day 1

Leucovorin 400 mg/m² IV infusion to match duration of irinotecan infusion, Day 1

5-FU 400 mg/m² IV bolus on Day 1, then 1200 mg/m²/day x 2 days IV continuous infusion

Repeat every 3 weeks

FOLFOXIRI Irinotecan + Oxaliplatin + Leucovorin + 5-FU

Irinotecan 165 mg/m² IV, Day 1

Oxaliplatin 85 mg/m² IV, Day 1

Leucovorin 400 mg/m² IV, Day 1

5-FU 1600 mg/m²/day for 2 days via IV continuous infusion

Repeat every 2 weeks

^*A lower dose may be used to reduce the potential for toxicity

Summary of Chemotherapy used in CRC

Chemotherapy Agents Used in CRC (Use May Be Recommended in Combination With Other Agents)
Agent	Uses
5-FU, with or without leucovorin (LV)	Neoadjuvant treatment of colon and rectal cancer Adjuvant treatment of colon and rectal cancer Management of mCRC
Capecitabine (Xeloda^®)	Neoadjuvant treatment of rectal cancer Adjuvant treatment of colon and rectal cancer Management of mCRC
Oxaliplatin (Eloxatin^®)	Adjuvant treatment of colon and rectal cancer Management of mCRC
Irinotecan (Camptosar^®)	Management of mCRC
Trifluridine-tipiracil (Lonsurf^®)	mCRC in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF targeted agent, and if RAS wild-type, an anti-EGFR therapy